PBCAR-19B is under clinical development by Precision Biosciences and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase I drugs for Mantle Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PBCAR-19B’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PBCAR-19B overview

PBCAR-19B is under development for the treatment of relapsed or refractory diffuse large B cell lymphoma and mantle cell lymphoma. The drug candidate comprises T cells expressing chimeric antigen receptor (CAR). It is administered by the intravenous route. It acts by targeting CD19. The drug candidate is being developed using electroporation technologies and ARCUS genome-editing technology. It is a genome editing platform derived from a natural genome editing enzyme called homing endonuclease which incorporates Adeno-associated virus (AAV) vector.

Precision Biosciences overview

Precision Biosciences is a biotechnology company, that develops and commercializes gene therapy and cancer immunotherapy. The company intends to its ARCUS technology, a proprietary genome editing platform, which combines specificity and efficacy, on the development of food, fuel and feed-based products. Precision Biosciences ARCUS technology helps improve genes related to crop quality, yield, and performance traits and strives to advance food products. The company also applies its ARCUS technology to the development of cell-based immunotherapies to cure genetic diseases. Precision Biosciences genome editing platform is derived from a natural genome editing enzyme, homing endonuclease. The company partners with various pharmaceutical and biotech companies to develop novel therapies for the treatment of cancer. Precision Biosciences is headquartered in Durham, North Carolina, the US.

For a complete picture of PBCAR-19B’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.